Mr. Paul Reid:

I will answer the Deputy's question giving a few perspectives. Last week, we summarised on the issue around PPE. There was a significant write-down, which is an accounting issue in terms of the realisable value at the year end, of the stock in total. As part of that, there was an approximately €64 million cost in regard to PPE suits. The preference is always to have gowns applied in terms of PPE for clinical front-line staff. When gowns became available at a later stage in the pandemic, we moved to the use of gowns. That was part of the issue. There were other issues, as just mentioned by the Deputy, in terms of the hand sanitisers based on a specification by the Department of Agriculture, Food and Marine, which were recovered from the system and placed in quarantine. There was a value associated with those as well. As far as I understand it, there were issues with FFP2 masks as well. They are the issues to which I can point straight away. The write-down value in total, as stated last week, included the €64 million in terms of suits.

Mr. Mulvany might want to add to my response.